Collegium Pharmaceutical ... (COLL)
Collegium Pharmaceutical Statistics
Share Statistics
Collegium Pharmaceutical has 32.25M shares outstanding. The number of shares has increased by 0.91% in one year.
| Shares Outstanding | 32.25M |
| Shares Change (YoY) | 0.91% |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 30.94M |
| Failed to Deliver (FTD) Shares | 13.4K |
| FTD / Avg. Volume | 3.2% |
Short Selling Information
The latest short interest is 5.62M, so 17.41% of the outstanding shares have been sold short.
| Short Interest | 5.62M |
| Short % of Shares Out | 17.41% |
| Short % of Float | 18.04% |
| Short Ratio (days to cover) | 11.21 |
Valuation Ratios
The PE ratio is 21.57 and the forward PE ratio is 4.94. Collegium Pharmaceutical 's PEG ratio is -0.07.
| PE Ratio | 21.57 |
| Forward PE | 4.94 |
| PS Ratio | 1.83 |
| Forward PS | 1.5 |
| PB Ratio | 5.31 |
| P/FCF Ratio | 3.79 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Collegium Pharmaceutical Inc. has an Enterprise Value (EV) of 1.71B.
| EV / Earnings | 35.57 |
| EV / Sales | 3.02 |
| EV / EBITDA | 5.56 |
| EV / EBIT | 10.26 |
| EV / FCF | 6.24 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 3.45.
| Current Ratio | 1.17 |
| Quick Ratio | 1.1 |
| Debt / Equity | 3.45 |
| Total Debt / Capitalization | 77.53 |
| Cash Flow / Debt | 0.41 |
| Interest Coverage | 2 |
Financial Efficiency
Return on equity (ROE) is 0.25% and return on capital (ROIC) is 12.21%.
| Return on Equity (ROE) | 0.25% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 12.21% |
| Revenue Per Employee | 2.88M |
| Profits Per Employee | 244.44K |
| Employee Count | 197 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 7.44 |
Taxes
| Income Tax | 27.58M |
| Effective Tax Rate | 0.36 |
Stock Price Statistics
The stock price has increased by -9.33% in the last 52 weeks. The beta is 0.82, so Collegium Pharmaceutical 's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -9.33% |
| 50-Day Moving Average | 30.94 |
| 200-Day Moving Average | 33.69 |
| Relative Strength Index (RSI) | 40.96 |
| Average Volume (20 Days) | 419.06K |
Income Statement
In the last 12 months, Collegium Pharmaceutical had revenue of 566.77M and earned 48.16M in profits. Earnings per share was 1.6.
| Revenue | 566.77M |
| Gross Profit | 326.17M |
| Operating Income | 166.96M |
| Net Income | 48.16M |
| EBITDA | 308.33M |
| EBIT | 166.96M |
| Earnings Per Share (EPS) | 1.6 |
Balance Sheet
The company has 238.95M in cash and 674.28M in debt, giving a net cash position of -435.34M.
| Cash & Cash Equivalents | 238.95M |
| Total Debt | 674.28M |
| Net Cash | -435.34M |
| Retained Earnings | -233.19M |
| Total Assets | 1.64B |
| Working Capital | -15.62M |
Cash Flow
In the last 12 months, operating cash flow was 274.75M and capital expenditures -461K, giving a free cash flow of 274.29M.
| Operating Cash Flow | 274.75M |
| Capital Expenditures | -461K |
| Free Cash Flow | 274.29M |
| FCF Per Share | 8.13 |
Margins
Gross margin is 57.55%, with operating and profit margins of 29.46% and 8.5%.
| Gross Margin | 57.55% |
| Operating Margin | 29.46% |
| Pretax Margin | 13.36% |
| Profit Margin | 8.5% |
| EBITDA Margin | 54.4% |
| EBIT Margin | 29.46% |
| FCF Margin | 48.4% |
Dividends & Yields
COLL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.38% |
| FCF Yield | 28.59% |
Analyst Forecast
The average price target for COLL is $44, which is 47.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $44 |
| Price Target Difference | 47.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.02 |
| Piotroski F-Score | 7 |